Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $16 to $18.
Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $15 to $16.
NeuroPace (NASDAQ:NPCE) raises FY2025 sales outlook from $94.000 million-$98.000 million to $97.000 million-$98.000 million vs ...
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.19) by ...
Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $17 to $15.
